

22 SEPTEMBER 2020

TGA MEDICINAL CANNABIS POST MARKET SURVEY

ASX ANNOUNCEMENT

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) wishes to announce that the Therapeutic Goods Administration (“TGA”) recently published its post-market survey test results of 22 medicinal cannabis products, including the Company’s *LGP Classic 20:5* cannabis oil medicine. The Company confirms it has been advised the CBD content of its audited sample produced a result 1.7% below the minimum requirement.

Prior to releasing the *LGP Classic 20:5* medicine to market and in accordance with TGA requirements, the Company engaged an Australian Government-owned, National Association of Testing Authorities (“NATA”) accredited and TGA-regulated and licensed Good Manufacturing Practices (“GMP”) laboratory to conduct testing of the relevant medicines, and received test results that confirmed the medicine’s active ingredients were well within the tolerance for medicinal cannabis labelling.

The Company issued its *Therapeutic Goods Order No. 93 (Standard for Medicinal Cannabis)* (“TGO93”) declaration and released the medicines to market in good faith based solely on those results.

Given its use and reliance on a TGA-accredited laboratory for the release testing, the Company is disappointed with the divergence in test results produced by the TGA’s audit. The Company and its testing agency are working closely with the TGA to determine how the agency’s TGA-licensed testing methodology and the TGA’s own methodology have produced differing results. That work is ongoing.

The Company also wishes to assure patients and prescribers that the product batch of approximately 1,000 bottles in question has already been dispensed and was not required to be recalled. The safety of these medicines was also not affected by the testing results, and the Company continues to sell the *LGP Classic 20:5* product line. Given this, there is not expected to be a financial impact associated with the TGA’s finding.

personal use only





Until the relevant testing alignment has been completed and validated, the Company will test its medicines at another Government-owned, NATA and TGA-licensed testing laboratory, itself engaged by the TGA to perform corroboration testing. This is to assure patients and prescribers that all Little Green Pharma medicines continue to be tested to the highest quality and clearly meet their label claims.

Medicinal cannabis is a new and evolving industry in Australia. LGP welcomes the opportunity to work with the TGA and testing laboratories to improve standardization and ensure alignment between testing practices and chemical standards. The Company would also encourage a TGA-led effort to ensure all medicinal cannabis products in the Australian market are release-tested by GMP-licensed testing authorities in Australia under harmonized, accredited and validated conditions.

It is through this ongoing harmonization and consistent application of medicinal cannabis testing procedures that the TGA and the medicinal cannabis industry will continue to develop and nurture patient and prescriber trust and confidence in medicinal cannabis medicines. At Little Green Pharma, patient safety and medicine quality are at the heart of everything we do.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to be "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200



For personal use only



About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility in Western Australia and an exclusive partnership with a GMP-licensed pharmaceutical manufacturer for the production of its own-branded range of medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

For personal use only